 NOVATO, Calif., June 30, 2021 GLOBE NEWSWIRE -- Ultragenyx Pharmaceutical Inc. NASDAQ: RARE, a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced the appointment of Corsee Sanders, Ph.D., to the Board of Directors, effective June 29, 2021. Dr. Sanders, an experienced veteran of the biopharma industry, will serve as an independent director. 